Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.
about
General Catalytic Deficiency of Hepatitis C Virus RNA Polymerase with an S282T Mutation and Mutually Exclusive Resistance towards 2'-Modified Nucleotide AnaloguesLow primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, RwandaThe K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.Short communication: Transmitted drug resistance and molecular epidemiology in antiretroviral naive HIV type 1-infected patients in Rhode Island.It is time to consider third-line options in antiretroviral-experienced paediatric patients?Immune-mediated attenuation of HIV-1Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trialDeep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen.Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in UgandaTransmission networks of drug resistance acquired in primary/early stage HIV infection.The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patientsGenotypic and Phylogenetic Insights on Prevention of the Spread of HIV-1 and Drug Resistance in "Real-World" Settings.
P2860
Q27477760-8ECF6120-FFEE-4CFE-9CA7-C7D481246FA9Q28535266-0CDADDDB-231C-479E-A8CD-B8369FF3CC88Q33681279-6622CEBD-6642-4046-9907-6CCFCD3F39EAQ34624825-B307CCCC-BCC3-4380-9D4E-11209903A2E9Q35586657-299CE644-1634-4135-9019-034138CF2BADQ35798108-127F2603-11D2-4F00-B1A1-9C6A97B810A1Q35965440-6FE4F6A0-32BE-4597-8F45-AC8C28CFEA5CQ36023047-48B15954-7FF5-4174-84AD-E29DDBD367C5Q36246775-C6B7C370-02AB-4EF1-AFFB-B24128ED69E9Q37062207-62671D42-9EC1-40D4-8555-8E82E0944642Q37115372-1F70D3C8-F159-4563-B91B-AE98CBF47978Q37293650-8D6BB742-6E2E-409D-B772-B2846EA17659Q47560008-6C13860A-445D-41EA-9418-ED7CFD4E8FEE
P2860
Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Rationale for maintenance of t ...... reatment experienced patients.
@ast
Rationale for maintenance of t ...... reatment experienced patients.
@en
type
label
Rationale for maintenance of t ...... reatment experienced patients.
@ast
Rationale for maintenance of t ...... reatment experienced patients.
@en
prefLabel
Rationale for maintenance of t ...... reatment experienced patients.
@ast
Rationale for maintenance of t ...... reatment experienced patients.
@en
P2093
P1433
P1476
Rationale for maintenance of t ...... reatment experienced patients.
@en
P2093
P433
P577
2004-04-01T00:00:00Z